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Abstract: Novel drugs to treat tuberculosis are required and the identification of potential 
targets is important. Piperidinols have been identified as potential antimycobacterial agents 
(MIC < 5 μg/mL), which also inhibit mycobacterial arylamine N-acetyltransferase (NAT), 
an enzyme essential for mycobacterial survival inside macrophages. The NAT inhibition 
involves a prodrug-like mechanism in which activation leads to the formation of bioactive 
phenyl vinyl ketone (PVK). The PVK fragment selectively forms an adduct with the cysteine 
residue in the active site. Time dependent inhibition of the NAT enzyme from 
Mycobacterium marinum (M. marinum) demonstrates a covalent binding mechanism for all 
inhibitory piperidinol analogues. The structure activity relationship highlights the 
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importance of halide substitution on the piperidinol benzene ring. The structures of the NAT 
enzymes from M. marinum and M. tuberculosis, although 74% identical, have different 
residues in their active site clefts and allow the effects of amino acid substitutions to be 
assessed in understanding inhibitory potency. In addition, we have used the piperidinol  
3-dimensional shape and electrostatic properties to identify two additional distinct chemical 
scaffolds as inhibitors of NAT. While one of the scaffolds has anti-tubercular activity, both 
inhibit NAT but through a non-covalent mechanism. 
Keywords: tuberculosis; covalent inhibitors; piperidinols; arylamine N-acetyltransferase 
 
1. Introduction 
Although tuberculosis (TB) is treatable with well-established drugs, and even preventable through 
vaccination, the disease remains one of the leading causes of death by bacterial infection, being 
responsible for approximately two million deaths annually. Tuberculosis infects one-third of the human 
population. It is estimated that 8.6 million new infections occurred in 2012, and thus it affects more 
people today than at any other time in history [1,2]. Until very recently TB has not been in the research 
portfolios of most of the major pharmaceutical companies. This neglect is partly because the greatest 
burden of disease is in developing countries [2]. A significant proportion of TB cases and deaths occur 
in human immunodeficiency virus (HIV) positive people [2].  
The current drug treatment is more than 40 years old, while the vaccine is almost 100 years old. 
Although the existing TB treatment is effective against drug-susceptible bacilli, the continuation of 
treatment for at least six months is essential in order to kill persistent or slow growing strains [3]. The 
emergence of multi-drug resistant (MDR) and extensively-drug resistant (XDR) TB further adds to the 
burden [4] and requires treatment with second-line drugs, which are less effective, more toxic, and 
expensive. Recently totally-drug-resistant TB (TDR) has been reported [5,6]. 
Bedaquiline (TMC-207), which inhibits mycobacterial ATP synthase, was approved by the FDA as 
part of the treatment regimen for MDR-TB [7,8]. Thus, it is the first new TB drug since the introduction 
of rifampin in 1970 [9]. 
Although the availability of the M. tuberculosis genome and the identification of potential targets are 
leading to filling of the drug pipeline with agents such as benzothiazinones [10], new targets need to be 
identified to avoid the problem of drug resistance in the future. The need for the physicochemical 
properties of potential compounds also needs to be addressed to allow penetration of the uniquely 
impermeable cell envelope, and to find an escape from active drug efflux mechanism in mycobacteria. 
There is a history of the use of pro-drugs as anti-mycobacterials. Isoniazid, the front-line  
anti-tubercular, is a pro-drug, which is activated within the bacterium [11] and acts through a covalent 
binding mechanism within M. tuberculosis. Traditionally, medicinal chemists have been skeptical about 
covalent drugs because of concern regarding potential for off-target reactivity. However, there has 
recently been a resurgence of interest in covalent drugs, with their potential advantages being increasingly 
recognized [12]. 
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Compound 1, a piperidinol derivative, has been identified as a potent antimycobacterial  
(MIC < 5 μg/mL) which also inhibits mycobacterial arylamine N-acetyltransferase (NAT) (Figure 1) 
through a covalent mechanism of action [13]. The NAT enzyme in mycobacteria has been identified in 
several studies as a potential target for the treatment of tuberculosis in that the gene is part of a cluster 
essential for M. tuberculosis survival inside macrophage [14–16]. MMNAT (NAT enzyme from 
Mycobacterium marinum), at 74% identical has been exploited as a model for M. tuberculosis NAT 
(TBNAT) since the MMNAT enzyme is highly soluble and a crystal structure has been available for 
some time. Although recently a preparation of TBNAT and a crystal structure have been available, the 
protein from M. tuberculosis is much more difficult to handle and particularly in relation to obtaining 
the high concentrations which best support crystallization. 
Compound 1 has previously been investigated as a candidate for several therapeutic uses, including 
anti-inflammatory [17], anticancer [18], anticonvulsant [19], antimicrobial [20] and historically as an 
antitubercular [21]. Furthermore, compound 1 is a cyclic derivative of a Mannich-base that has been 
investigated as a prodrug vehicle for several therapeutic agents [22]. Understanding the key features of 
this scaffold is essential in progressing the development of the compound as a therapeutic agent.  
Figure 1. Specificity of 1 for prokaryotic N-acetyltransferase (NAT) enzymes. 
 
Compound 1 was tested at 30 μM against five pure recombinant NAT enzymes from M. smegmatis (MSNAT), 
S. typhimurium (STNAT), P. aeruginosa (PANAT) and also against two eukaryotic enzymes, hamster NAT2 
(shNAT2) and human NAT1. The NAT activity assay [23] was used to determine the specific activities of the 
pure recombinant NATs in the presence of compound 1. The results are shown as the mean ± S.D. of triplicate 
determinations of percentage inhibition of hydrolysis of Ac-CoA as described in the presence of 500 μM  
5-amino salicylic acid (5ASA) as substrates for all enzymes apart from TBNAT where 500 μM hydralazine (HLZ) 
has been used as a substrate. The inhibition is represented as a percentage compared to an uninhibited control.  
To this end, we report the evaluation of chemical modifications on the piperidinol scaffold using 
inhibition of mycobacterial NAT by compound 1 and its analogues in order to try to improve potency. 
We have also carried out in silico studies with the piperidinol scaffold as a query molecule to open up 
chemical space on the basis of 3D shape and electrostatics and have identified two new chemical 
scaffolds, which were subsequently found to be NAT inhibitors. We have investigated the compounds 
as inhibitors of mycobacterial growth. 
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2. Results and Discussion 
2.1. Mechanism of Inhibition 
Compound 1 has been identified as a selective inhibitor for bacterial and mycobacterial NATs [24,25]. 
The mechanism of NAT inhibition by this compound and its analogues has been elucidated and involves 
specific and unique covalent modification of the active site cysteine of NAT [13] (Figure 2). 
Figure 2. The mechanism of adduct formation. 
 
The adduct formation is proceeded by the formation of a reactive phenyl vinyl ketone (PVK). The PVK reaction 
with thiols resulted in the addition of a 3-Phenyl-3-oxopropyl moiety (POP) (when R1 is H) or a  
3-(4-Chlorophenyl)-3-oxopropyl moiety (when R1 is Cl). The expected differences in molecular weight of the 
added fragments are +132.07 Da and +166 Da, respectively.  
The NAT enzyme from M. marinum is 74% identical to NAT from M. tuberculosis and the M. marinum 
NAT enzyme has been studied as a model for the less stable M. tuberculosis enzyme [13,26,27]. 
Using a selected set of compound 1 analogues (Table 1), the inhibition was demonstrated to be 
irreversible and time-dependent using the recombinant NAT enzyme from M. marinum, MMNAT, as 
has previously been described for inhibition of NAT from M. tuberculosis [13] (Table 1 and Figure S1 
in Supplementary Materials). To facilitate comparison of the compounds, the values of the apparent 
inactivation half-life of the enzyme were calculated in the presence of the different compounds from kobs 
as shown in Table 1. Potent inhibitors are predicted to exhibit a shorter inactivation half-life [28]. An 
adduct is formed, in which a phenyl vinyl ketone moiety (PVK) is directly conjugated to the active site 
cysteine sulfhydryl group [13]. For compounds 2, 3 and 5, the structure of the inhibitor has a halide 
substituent on the para position of the benzene ring (position R1, Table 1), and thus the adduct formed 
with the active site cysteine is predicted to be larger than the benzene ring unsubstituted at the para 
position, as is observed by mass spectroscopy analysis [13]. 
The piperidinols exhibited the same type of inhibition against the homologue of NAT from  
M. tuberculosis, TBNAT, which is 74% identical in sequence to MMNAT and shares the key features 
of the binding pocket. Whilst the inhibition was more rapid with TBNAT than with MMNAT, higher 
concentrations of inhibitor were required compared to those used with MMNAT. The mechanism of 
activation of the compounds have been described in Abuhammad et al., 2012 and is proposed to procede 
by a nucleophilic attack on the piperidinol ring carbonyl. We have not been able to ascertain whether 
the activation is enzyme catalyzed or is due to hydrolysis within the binding pocket. However, it is likely 
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that the binding of the compounds into the active site promote the formation of the active intermediate 
since only the active site Cys is modified. If the active species were formed through hydrolysis without 
binding to the enzyme a priori, this would be likely to result in a random modification of all of the 
cysteine residues. 
Table 1. The time-dependent activity of the piperidinols against MMNAT. 
 
Code R1 R2 kobs (10−3 min−1) t1/2 (min) 
Critical Volume 
(cm3/mol) 
cLogP 
1 H -CH3 9 ± 2 81.5 864.5 2.41 
2 Cl -CH3 110 ± 2 6.3 962.5 3.53 
3 Br -CH3 74 ± 7 9.4 988.5 4.07 
4 H -CH2CH3 15 ± 1 45.6 920.5 2.75 
5 F -CH2CH3 638 ± 120 1.1 956.5 3.07 
6 H -(CH2)3CH3 104 ± 8 6.6 1032.5 3.66 
7 H 
 
573 ± 25 1.2 1077.5 3.96 
8 H 
 
10 ± 1 71.4 1092.5 4.15 
9 H 
 
163 ± 39 4.2 994.5 2.84 
10 H 
 
19 ± 1 37.1 1017.5 0.91 
11 H 
 
34 ± 1 20.2 1276.5 3.06 
The assay was performed as described in Methods and kobs values were obtained from the slope of the  
semi-logarithmic plots of the residual activity vs. incubation time at 11.9 μM except for 5, 7 and 11 (5.9 μM) 
and 10 (23.8 μM). The results are presented as the mean ± S.D. of triplicate measurements at 24 °C. t1/2 is the 
apparent inactivation half-life calculated from kobs (t1/2 = 0.693/kobs). The critical volumes (the volume of one 
mole of material at the critical temperature and pressure) and cLogP values (the octanol-water partition 
constant) as predicted by ChemBioDraw Ultra 12.0 [29] are shown. Compounds 1, 2, 7 and 11 have been 
described previously [13] and are included for full comparison. 
2.2. Effects of Substitutions on the Piperidinol Scaffold 
When the phenyl ring was para substituted with a halide, the resulting piperidinols (2, 3 and 5) 
displayed an increase in the inactivation potency as evidenced by the shorter inactivation half time (Table 1) 
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than the benzene ring unsubstituted at the para position. The fluoro derivative (5) showed a low 
inactivation time (Table 1). The ethyl substituent on the nitrogen atom in 5 is likely to contribute to the 
increased inactivation potency since the ethyl piperidinol 4 with no halide substituent, shows twice the 
activity of the methyl derivative 1. However, other factors, for example the chemical stability of the 
compounds, could well contribute to their relative protein inactivation activities.  
Increasing the length of the alkyl chain on the piperidinol nitrogen results in increased inhibition  
(as measured by the rate; Table 1; compounds 1, 4 and 6). However, this is unlikely to be due to 
hydrophobicity alone, because there is a significant difference in activity between the potent cyclohexyl 
analogue, compound 7, and the weak benzyl analogue, compound 8, despite both compounds having 
similar clogP values (Table 1, Figure S2 in Supplementary Materials). The cyclohexyl ring has a strong 
preference to adopt a chair conformation whilst the ring of the phenyl is planar. Furthermore, the extra 
methylene in the benzyl group inserts two rotatable bonds not present in the cyclohexyl compound, 
making it more conformationally flexible, as well as significantly altering the geometry of the 
attachment. Either of these points could contribute to reduced activity of the benzyl compound despite 
increased bulk. 
Although there is no simple correlation with hydrophobicity, it appears to be important since highly 
polar R2 substituents result in poor inhibition of MMNAT. In addition to hydrophobicity factors, the 
volume of the inhibitors appears to be a contributing factor to inhibitory potency (Table 1). Except for 
compounds 3, 7 and 10, the inhibitor potency was found to increase linearly as the critical molar volume 
of the molecule increased (Table 1).  
2.3. Comparison of MMNAT and TBNAT 
TBNAT and MMNAT, although being 74% identical in sequence, show different substrate and 
inhibition profiles [30]. To provide a basis for a qualitative comparison of MMNAT and TBNAT 
inhibition by the piperindols, IC50 analyses were carried out. The IC50 values were comparable for 
inhibitors 1–6 and 11; however, there is a difference between the activities of inhibitors 8–10 when 
tested against MMNAT compared with TBNAT (Table 2). 
Evidence for binding of the piperdinols in close proximity to the methionine moieties Met209 and 
Met222 of MMNAT can be deduced from structural studies on the MMNAT complexed with  
compound 1 [31]. The refinement the crystal structure of MMNAT soaked with compound 1, shows 
patches of electron density, contiguous with the methionine residues (Met209 and Met222) and the 
tryptophan Trp97, indicating the presence of a bound chemical entity(ies). The aromatic rings and the 
methylamine moiety of 1 have been modelled into these electron density patches (hypothetical model, 
Figure S3, Supplementary Materials). Notably, this electron density was absent in all other MMNAT 
structures (PDB entries 2vfb, 2vfc [32]; and 3ltw [27]), excluding the possibility that it was due to 
components from the expression system or from the crystallization cocktail as has been observed in e.g., 
NAT from Bacillus anthracis [33]. The interpretation of the electron density is proposed to be caused 
by the presence of the ligand in the enzyme’s active site before activation into the reactive intermediates. 
It is proposed that once the piperidinol is activated to the PVK fragment (Figure 2) the fragment is likely 
to react immediately with the active site cysteine. It is possible that the piperidinol fragment may be 
activated by the enzyme acting as a catalyst despite the relatively acidic pH (6.5) at which the crystals 
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grew, as the enzyme was shown to maintain a stable catalytic (acetyl-transfer) activity within a pH range 
of 6–9. However, further evaluation of the pH stability of the piperidinols would need to be pursued for 
drug design. 
Therefore, we hypothesize that the piperidinols bind at this location within the MMNAT binding 
pocket. This region within the binding pocket varies significantly between MMNAT and TBNAT [34] 
(Figure 3) and is likely to explain the difference in the inactivation rate of these inhibitors on both 
enzymes (Table 2). The binding pocket of the TBNAT appears to be more charged and polar, compared 
to that of MMNAT [34]. The two methionine residues (Met209 and Met222) within this region of the 
binding pocket in MMNAT are substituted with tyrosine and serine in TBNAT, whilst the two leucine 
residues (Leu98 and Leu151) and methionine (Met133) are substituted with lysine, histidine and 
glutamine, respectively (Figure 3). This architecture is proposed to explain the reduced affinity of the 
piperidinols for TBNAT as evidenced by the need for higher concentrations to inhibit the TBNAT, 
although the rate of inactivation with TBNAT is faster than with MMNAT. 
Figure 3. Comparison of the binding pockets of TBNAT and MMNAT. A ribbon 
representation shows the main residues in the binding pocket of (A) TBNAT and (PDB code 
4BGF, 2.1 Å) and (B) MMNAT (PDB code 2VFB; 2.1 Å). 
 
2.4. Effect on Mycobacteria 
The compounds were also assessed for in vitro anti-mycobacterial activity against M. bovis BCG and 
the M. tuberculosis strain H37Rv (Table 2). All nine compounds showed promising antimycobacterial 
activity against M. tuberculosis, with an MIC below 10 μg/mL (Table 2). 
In the absence of experimental evidence on comparison of uptake into M. tuberculosis and M. bovis 
BCG it is not possible to speculate on the reason for the minor differences. Nevertheless, the fact that 
these compounds do have activity in inhibiting growth identifies that they are of interest.  
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Table 2. The inhibitory activity of compound 1 and its analogues a. 
 
Code R1 R2 
TBNAT MMNAT MIC (μg/mL) 
% Inhibition 
IC50 (μM) 
HLZ 
% Inhibition 
IC50 (μM) 
HLZ 
IC50 (μM) 
5ASA 
M. bovis BCG M. tuberculosis 
1 H -CH3 101 ± 1 7.7 ± 0.9 105 ± 1 1.3 ± 0.0 6.0 ±1 6.3–12.5 1–10 
2 Cl -CH3 98 ± 1 1.6 ± 0.1 103 ± 2 0.16 ± 0.01 1.4 ± 0.6 6.3–12.5 ND 
3 Br -CH3 98 ± 3 2.9 ± 0.4 99 ± 1 0.08 ± 0.01 1.3 ± 0.4 6.3–12.5 5–10 
4 H -CH2CH3 72 ± 4 7.3 ± 0.3 126 ± 5 1.9 ± 0.0 8.0 ± 1 6.3–12.5 5–10 
5 F -CH2CH3 108 ± 1 4.4 ± 0.0 102 ± 3 0.5 ± 0.0 1.3 ± 0.5 6.3–12.5 5–10 
6 H -(CH2)3CH3 100 ± 3 6.9 ± 0.4 102 ± 3 2.6 ± 1 5.0 ± 0.4 6.3–12.5 1–5 
7 H 
 
72 ± 60 4.4 ± 0.1 103 ± 1 ND 1.7 ± 0.2 6.3–12.5 1–5 
8 H 
 
58 ± 2 ND 101 ± 1 4.1 ± 0.4 ND 6.3–12.5 0–1 
9 H 
 
51 ± 3 ND 100.8 ± 0.5 2.5 ± 0.3 9.0 ± 0.9 ND 0–1 
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Table 2. Cont. 
Code R1 R2 
TBNAT MMNAT MIC (μg/mL) 
% Inhibition 
IC50 (μM) 
HLZ 
% Inhibition 
IC50 (μM) 
HLZ 
IC50 (μM) 
5ASA 
M. bovis BCG M. tuberculosis 
10 H 
 
47 ± 2 ND 99 ± 0.7 13 ± 1 >30 3.1–6.3 ND 
11 H 
 
67 ± 4 1.1 ± 0.3 100 ± 2 2.7 ± 0.4 1.1 ± 0.3 6.3–12.5 1–5 
a NAT activity was measured by a NAT-inhibition assay using 150 μM HLZ and 120 μM Ac-CoA as substrate. The percentage of enzyme inhibition was measured in the 
presence of 50 μM inhibitor and compared to the un-inhibited control. The IC50 values were determined by measuring the enzyme activity in the presence of variable 
concentrations of each inhibitor (0–250 μM) and compared to the un-inhibited control. The results are presented as the mean ± S.D. of triplicate measurements. ND is not 
determined. Inhibition curves were obtained by non-linear fitting of the% inhibition and the inhibitor concentration (μM) using the Log(inhibitor) vs. response module of 
GraphPad Prism 5.0. 
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2.5. In Silico Screening 
The piperidinols are chiral molecules and the identification of other active chemotypes is desirable. 
Previously, ligand-based virtual screening for NAT inhibitors based on the 3D shape of compound 1 has 
proven very useful for identifying inhibitors of a distinct NAT homologue in humans [35]. Since then, a 
new methodology (ElectroShape) has been developed which includes an electrostatic comparison in the 
molecular similarity description in addition to shape [36,37]. Importantly, given the chiral nature of the 
query molecule, the molecular representation used by ElectroShape is sensitive to chirality, which was 
not the case in the previous work [38]. Screening for novel NAT inhibitors based on the 3D shape and 
electrostatic comparison of compound 1 was performed using the ElectroShape approach. A conformational 
model was generated for compound 1 after which it was used as a search query against a database of  
7.3 million commercially-available molecules, Scopius (InhibOx Ltd., Oxford, UK). The identified hits 
were ranked based on the ElectroShape score and 12 compounds out of the top 100 hits were purchased 
and tested for their NAT inhibition activity. The chemical structures of the tested molecules and their 
inhibition activities are shown in Table S1 in Supplementary Materiala. Among these inhibitors, 
compounds 15 and 16 show NAT inhibition activities (Figure 4 and Figure S4 in Supplementary 
Materials). Although both 15 and 16 show high potency against MMNAT, only compound 15 shows 
inhibition of TBNAT. 
Figure 4. Active hits obtained by in silico 3D-shape screening. 
 
The ability to identify inhibitors based on the 3D shape and electronic properties of compound 1 
supports the affinity of the intact piperidinols to the NAT binding pocket substantiates, but does not 
prove, that the binding of the compounds into the active site promote the formation of the active 
intermediate. Although the search query molecule 1 acts via covalent bond formation, the hits obtained 
show no covalent adduct formation as was confirmed by mass spectroscopy analysis (data are not 
shown). Interestingly, compound 15 shows also antimycobacterial activity with MIC of 125–250 μM 
(33–66 µg/mL) against M. bovis BCG (Figure S5 in Supplementary Material). 
3. Experimental Section 
All chemicals and reagents were purchased from Sigma Aldrich (Poole, Dorset, UK), unless 
otherwise stated. Data analysis was carried out using GraphPad Prism 5.0. The critical volumes and 
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cLogP values were predicted by ChemBioDraw Ultra 12.0 [29]. Structural figures and graphical 
renderings were made with Discovery Studio (DS) Visualizer 3.1 [39]. 
3.1. Range of Inhibitors 
Compound 1 which was identified from a previous high throughput screen was synthesized ab initio 
to confirm its identity and activities as previously described [40]. It has been confirmed separately that 
during the cyclisation only the diastereoisomer 1 depicted in Scheme 1 was formed [40]. The compound 
was obtained in 79% yield, with greater than 99.5% purity as determined by reverse phase HPLC. 
Scheme 1. Reagents and conditions: (i) MeNH2·HCl, paraformaldehyde, cat. ZnCl2, MeCN, 
Δ, 16 h; (ii) NaOH. 
 
Halogenated analogues 2 and 3 were either purchased from Chembridge, (San Diego, CA, USA) 
(compound 2) or synthesized by cyclisation of the intermediate bis-Mannich bases with NaOH, which 
following recrystallization of the products furnished the corresponding piperidinols (compound 3; 
Scheme 1). 
To investigate further the structural influence of N functionality over both NAT inhibition and 
antimycobacterial activity, eight commercially available compounds (4–11, Cheshire Biosciences, 
Chester, UK) with different substitutions at the piperidinol nitrogen were selected for testing. All 
compounds were the best available grade. All compounds were greater than 95% pure apart from 
compound 4, which was only 80% pure. Stock solutions of the all compounds were prepared at  
5–50 mM in DMSO and stored at −20 °C. 
3.2. Enzyme Production 
The NAT enzymes from M. smegmatis [41], S. typhimurium [42], P. aeruginosa [43], M. marinum [32], 
M. tuberculosis [44], hamster NAT2 [45] and human NAT1 [46] were produced as recombinant proteins, 
purified as previously described and stored at −80 in 20 mM Tris-HCl pH 8 containing 1 mM 
dithiothreitol and 5% glycerol and thawed and used within 1–5 h. 
3.3. NAT Inhibition Assay 
An assay for measuring the formation of CoA [23] was modified and used to determine the activity 
of the enzyme in the presence of potential inhibitors exactly as described previously [13]. Irreversible 
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inhibition, progressive with time was measured for the piperidinol inhibitors by the protocol described 
in [13] and the values of the apparent first order rate constant (kobs) were determined using the Kitz and 
Wilson model [28]. Adduct formation was determined as previously described by mass spectroscopy 
analysis [13]. 
3.4. Mycobacterial Growth Inhibition in Vitro 
Mycobacterial growth inhibition was measured in one of two ways: on agar and in liquid culture. 
Mycobacteria (M. bovis BCG and M. tuberculosis H37Rv) were grown as spot cultures in  
6-well plates on solid medium (Middlebrook 7H10 medium supplemented with 10% (v/v) oleic  
acid-albumin-dextrosecatalase (OADC)) as previously described [14,47], with test compounds at the 
concentrations indicated in the text. Test compounds were added to the melted, partially cooled  
7H10-OADC agar medium as solutions in DMSO, and the final concentration of DMSO in each well 
was 0.1% (v/v). The minimum inhibitory concentration (MIC) is defined as the concentration of inhibitor 
at which no growth of mycobacteria was detected after a period of 2 weeks. Compound 1 and its 
analogues that showed MIC below 5 μg/mL (6–9 and 11; Table 2) were tested in vitro for their cytotoxic 
effect on RAW 264.7 cells as previously described [48] and no cytotoxicity was observed at up to  
50 μg/mL inhibitor concentration.  
3.5. Alamar Blue Assay 
The Alamar blue assay was used to determine the antimycobacterial activity of NAT inhibitors 
against M. bovis BCG str. Pasteur (ATCC 35734) [49,50]. 
M. bovis BCG (100 mL) was grown until early log-phase (OD600 0.4–0.7). The cells were harvested 
(2500 g, 15 min), resuspended (50 mL phosphate-buffered saline (PBS), 0.05% Tween 80) and harvested 
(25,000 g, 15 min). The cells were resuspended (4 mL PBS, 0.05% Tween 80), aliquoted (100 μL) per 
cryo-tube and snap frozen in liquid nitrogen and stored at −80 °C. 7H9GC-OADC (2.4 mL) was added 
to 100 μL of cells and diluted 100-fold in 7H9GC-OADC. The assay was carried out in 96-well plates 
in the presence of either compound 4, and INH as control (0–66 μg/mL in DMSO). Plates were incubated 
at 37 °C in the case of M. bovis BCG. Alamar Blue dye (50 μL) was added after six days for M. bovis 
BCG. The minimum inhibitory constant (MIC) was determined visually at the concentration at which 
color-change occurred (blue to pink). 
3.6. In Silico Shape-Based Screening 
In silico screening for potential NAT inhibitors was performed using the ElectroShape approach [37]. 
ElectroShape requires as input a three-dimensional representation of the query molecule, compound 1. 
Because of the uncertainties around the specific bioactive conformation, a conformational model was 
constructed which consists of a representative set of low-energy conformations. Conformations were 
generated using the program Conform [51] keeping conformations within 10 kcal.mole of the global 
minimum and with a minimum RMSD between them of 0.5 Å. This conformational model was used as 
the query to screen the Scopius database of commercially available molecules (InhibOx Ltd., Oxford, 
UK). Scopius represents a consolidation of commercially available compounds from over 200 vendors 
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worldwide. Only the drug-like compounds in Scopius, 7.3 million, were included in the virtual screening 
study. Drug-like compounds comply with Lipinski-like physicochemical properties and do not contain 
substructures (represented as SMARTS patterns) known to be problematic for lead optimization. The 
identified hits were ranked based on the ElecroShape score and 12 compounds of the top 100 hits were 
purchased and tested for their NAT inhibition activity. 
4. Conclusions 
The piperidinol scaffold was identified as a selective prokaryotic NAT inhibitor that exhibits potent 
antimycobacterial activity. The mechanism of inhibition of the NAT enzymes was confirmed previously 
by mass spectroscopy analysis and X-ray 3D-structure determination of the MMNAT enzyme with 
compound 1 [13]. The mechanism of NAT inhibition, which combines activation followed by covalent 
modification, presents an attractive starting point for novel anti-tubercular agents. Whilst NAT has been 
shown to be essential for intracellular survival of mycobacteria, it is likely that the piperidinols inhibit 
mycobacterial growth via inactivation of other targets also. Considering both the concept of polypharmacy 
and the resistance problems associated with TB treatment, more than one target is highly desirable. 
In an attempt to improve antimycobacterial action and inhibition of NAT enzymic activity, we have 
studied a series of analogues with selective structural modifications. We have tested antimycobacterial 
actions on M. bovis BCG and M. tuberculosis and have used pure recombinant NAT enzymes from  
M. marinum and M. tuberculosis. The halogenation of the para position of the benzene rings as well as 
a hydrophobic N functionality showed improvement of the inhibition of MMNAT. The library of 
piperidinols tested exhibit different activity against MMNAT and TBNAT, despite the high sequence 
similarity between both enzymes. This is likely to be associated with the subtle differences in the 
architecture of the binding pocket of MMNAT and TBNAT. 
Two new scaffolds of NAT inhibitors have been identified in silico using the 3D-shape and 
electrostatic modeling of compound 1 as a query molecule. The results demonstrate that the intact 
piperidinols have structural complementarity to the binding pocket of MMNAT such that non-specific 
affinity to the enzyme is excluded. Compound 15 identified through shape comparison was also 
demonstrated to inhibit the growth of M. bovis BCG. 
The results clearly highlight the importance of the piperidinol scaffold as a lead in antimicrobial drugs 
development and underline the benefits of extending the number of new chemical entities through  
in silico methods. 
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